Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Unknown 62Recruiting 59Completed 40Not yet recruiting 27Active not recruiting 15Withdrawn 9Terminated 5Enrolling by invitation 3Suspended 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Head & Neck 1

Conditions

Liver Neoplasms 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 7Specimen Handling 6Oxaliplatin 5Irinotecan 5S 1 (combination) 4Magnetic Resonance Spectroscopy 4Leucovorin 4Fluorouracil 4Capecitabine 4Biopsy 4Bevacizumab 4Radiotherapy 3Nivolumab 3Immunotherapy 3Drug Therapy 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3trifluridine tipiracil drug combination 2titanium silicide 2spartalizumab 2lenvatinib 2aldesleukin 2Taxes 2Surgical Procedures, Operative 2Radiosurgery 2Photochemotherapy 2Interleukin-2 2Endoscopic Mucosal Resection 2Cyclophosphamide 2Cisplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Suspended × lenvatinib × Gastrointestinal × Clear all
NCT05033522 2025-10-23

ALIVE

Mirror Biologics, Inc.

Phase 2/3 Suspended
150 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03779100 2019-01-28

Lenvatinib Plus PD-1 Antibody for Unresectable ICC

Sun Yat-sen University

Phase 2 Suspended
25 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡